Biosimilar Onslaught Dents Global Blockbuster Humira

Biosimilar Onslaught Dents Global Blockbuster Humira

Humira logo (Photo: Humira) The dominance of the autoimmune disease treatment Humira (active ingredient: adalimumab), once the world’s best-selling drug, is waning. Sandoz’s biosimilar Hyrimoz has rapidly gained market share, pulling down Humira’s share, with Samsung Bioepis’ Hadlima closely following. … Read more